注射用丹参多酚酸对缺血性脑卒中患者的安全性评价

目的 观察注射用丹参多酚酸对缺血性脑卒中患者的生命体征和肝、肾功能变化状况,评价该药物在临床应用中的安全性.方法 将40例缺血性脑卒中患者根据其合并用药情况分为无合并用药组（A组,8例）、合并使用降压药组（B组,12例）和合并使用治疗脑梗死口服药物（C组,20例）3个组,对所有患者连续静脉滴注丹参多酚酸14天,在患者用药前和用药结束后3天内分别进行常规体格检查和肝、肾功能检测,并对结果进行分析.结果 40例患者3个组别,组内比较时,患者生命体征和肝肾功能指标用药前后的差异均无统计学意义（P＞0.05）.组间两两比较时,除了B组与C组患者用药后的舒张压、A组与B组患者用药后的肝功能ALT,差异具有统计学意义;其余组间比较,患者生命体征和肝肾功能指标用药前后,差异均无统计学意义（P＞0.05）.结论 注射用丹参多酚酸对缺血性脑卒中患者的生命体征和肝、肾功能影响甚小,该药物在临床应用中比较安全.

Injection salvianolate ischemic stroke patient safety evaluation

Objective To observe the injection salvianolate ischemic stroke patient＇s vital signs and liver and kidney function status, evaluation of the drug in the clinical application of security. Methods 40 patients with ischemic stroke were divided according to their combined medication without combination therapy group （A, 8 cases）, the combined use of antihypertensive medication group （B group, 12 cases） and the combined use of oral medication treatment of cerebral infarction （C group, 20 cases） 3 groups, continuous intravenous infusion for all patients salvianolate 14 days, in patients before treatment and after three days, respectively, for routine physical examination, and liver and kidney function tests, and the results for analysis. Results 40 patients three categories, comparison group, each group within the group of patients vital signs and indicators of liver and kidney function before and after treatment showed no significant difference （P〉 0.05）. Comparison between two groups, except for group B and group C patients after treatment of diastolic blood pressure, A group and B group patients after treatment, liver function ALT, a statistically significant difference; remaining between the two groups, patient vital signs and liver and kidney function parameters before and after treatment, the difference was not statistically significant function has （P〉 0.05）. Conclusion injection salvianolate ischemic stroke patient＇s vital signs and liver and kidney little influence on the drug in clinical applications safer.